Chang Ji Hui Zu Zi Zhi Zhou

Researchers are conducting a nationwide, multicenter observational study to establish and improve a hospital-based clinical surveillance and early warning system for respiratory syndrome pathogens. The study will include patients with respiratory syndrome from various hospital settings across seven regions in China. It aims to monitor pathogen trends, support risk assessment, and provide evidence for prevention and control strategies over several years. Participants diagnosed with respiratory syndrome will have clinical data collected every two weeks, including demographics, symptoms, diagnoses, lab tests, medications, oxygen therapy, hospital stays, ICU admissions, and outcomes. For those meeting specific diagnostic criteria, respiratory and other biospecimens will undergo a range of tests including routine pathogen tests, multiplex PCR, targeted and metagenomic sequencing, antibody and cytokine testing, and exploratory multi-omics analyses. During the study, data and specimens will be collected routinely from participants receiving clinical care. Researchers will generate national and regional surveillance reports to support early warnings and prevention efforts. The main outcomes measured include detection rates and types of respiratory pathogens and immune responses after infection or vaccination, tracked over three years. Participation involves regular data reporting through secure channels without additional treatment interventions.

Researchers are evaluating the effect of ShengXian-QuYu Decoction on quality of life, symptoms, and biomarkers in patients with heart failure who have reduced or mildly reduced ejection fraction. This is a nationwide, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to assess this traditional Chinese medicine compared to a placebo alongside standard care. The trial will also analyze results within subgroups based on factors like heart failure characteristics, comorbidities, and baseline biomarkers. Participants will be randomly assigned to receive either the ShengXian-QuYu Decoction or a placebo, both given orally twice daily. The decoction contains specific herbal ingredients including Astragalus membranaceus and Panax ginseng, among others. The study treatment is added to each patients usual care, and the effects will be monitored over a 12-week period, with some measures extending up to 26 weeks. During the study, participants will undergo various assessments including quality of life questionnaires, symptom scoring based on Traditional Chinese Medicine standards, exercise capacity tests, and measurement of heart function and kidney filtration. Biomarkers such as N-terminal pro-brain natriuretic peptide will also be tracked. Safety and adherence will be monitored throughout the study, which started in March 2023 and is expected to complete by the end of 2025.